Biotech firm receives patent for psilocybin-derived mental health therapeutics [Helio]
Monday, October 2, 2023 1 min read
Key Takeaway: A biotechnology firm based in the Boston area has secured a patent for its EVM301 series of psilocybin-derived molecules. This patent, titled 'Carboxylated Psilocybin Derivatives and Methods of Using,' is aimed at treating various mental health disorders. The development marks a significant step in the firm's efforts to innovate in mental health therapeutics.
Market Sentiment Analysis
POSITIVE FACTORS
The firm has successfully secured a patent.
The patent covers innovative psilocybin-derived therapeutics.
The EVM301 series aims to address mental health disorders.
Full Press Release Details
A Boston-area biotechnology firm announced it has received a patent titled “Carboxylated Psilocybin Derivatives and Methods of Using” for its EVM301 series of molecules to treat a range of mental health disorders.
Full Article
Frequently Asked Questions
What is the patent received by the biotech firm for?
The patent is for psilocybin-derived molecules aimed at treating mental health disorders.
What is the title of the patent granted?
The patent is titled 'Carboxylated Psilocybin Derivatives and Methods of Using.'
What series of molecules does the patent cover?
The patent covers the firm's EVM301 series of molecules.